Mesoblast Limited (ASX: MSB) has strengthened its balance sheet by refinancing existing debt through a new five-year credit line of up to US$125 million from Dr Gregory George, a major shareholder and board member. The company has already drawn US$75 million, which was used to fully retire its senior secured loan and partially repay a subordinated royalty facility, materially reducing financing risk. The remaining US$50 million remains available at Mesoblast’s discretion until June 30, 2026.
The facility carries a fixed interest rate of 8.00% per annum with an interest-only structure over the full five-year term, representing a meaningful reduction in borrowing costs. Importantly, the arrangement is non-dilutive, offers full prepayment flexibility without penalties, and does not place restrictions on future unsecured debt or licensing activity. Until residual obligations are settled, the facility remains unsecured and ultimately will be backed only by a specific royalty stream, preserving operational and strategic flexibility.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Mesoblast Secures Lower-Cost, Non-Dilutive Five-Year Credit Facility
Mesoblast Limited (ASX: MSB) has strengthened its balance sheet by refinancing existing debt through a new five-year credit line of up to US$125 million from Dr Gregory George, a major shareholder and board member. The company has already drawn US$75 million, which was used to fully retire its senior secured loan and partially repay a subordinated royalty facility, materially reducing financing risk. The remaining US$50 million remains available at Mesoblast’s discretion until June 30, 2026.
The facility carries a fixed interest rate of 8.00% per annum with an interest-only structure over the full five-year term, representing a meaningful reduction in borrowing costs. Importantly, the arrangement is non-dilutive, offers full prepayment flexibility without penalties, and does not place restrictions on future unsecured debt or licensing activity. Until residual obligations are settled, the facility remains unsecured and ultimately will be backed only by a specific royalty stream, preserving operational and strategic flexibility.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au